253 related articles for article (PubMed ID: 11526483)
21. E2F activity is essential for survival of Myc-overexpressing human cancer cells.
Santoni-Rugiu E; Duro D; Farkas T; Mathiasen IS; Jäättelä M; Bartek J; Lukas J
Oncogene; 2002 Sep; 21(42):6498-509. PubMed ID: 12226753
[TBL] [Abstract][Full Text] [Related]
22. Disruption of Rb/E2F pathway results in increased cyclooxygenase-2 expression and activity in prostate epithelial cells.
Davis JN; McCabe MT; Hayward SW; Park JM; Day ML
Cancer Res; 2005 May; 65(9):3633-42. PubMed ID: 15867358
[TBL] [Abstract][Full Text] [Related]
23. Microarray screening for target genes of the proto-oncogene PLAG1.
Voz ML; Mathys J; Hensen K; Pendeville H; Van Valckenborgh I; Van Huffel C; Chavez M; Van Damme B; De Moor B; Moreau Y; Van de Ven WJ
Oncogene; 2004 Jan; 23(1):179-91. PubMed ID: 14712223
[TBL] [Abstract][Full Text] [Related]
24. The tumor suppressor KLF11 mediates a novel mechanism in transforming growth factor beta-induced growth inhibition that is inactivated in pancreatic cancer.
Buck A; Buchholz M; Wagner M; Adler G; Gress T; Ellenrieder V
Mol Cancer Res; 2006 Nov; 4(11):861-72. PubMed ID: 17114344
[TBL] [Abstract][Full Text] [Related]
25. [Micro-RNA and oncogenesis].
Bénard J; Douc-Rasy S
Bull Cancer; 2005 Sep; 92(9):757-62. PubMed ID: 16203264
[TBL] [Abstract][Full Text] [Related]
26. Transcriptional regulation of the mouse PNRC2 promoter by the nuclear factor Y (NFY) and E2F1.
Zhou D; Masri S; Ye JJ; Chen S
Gene; 2005 Nov; 361():89-100. PubMed ID: 16181749
[TBL] [Abstract][Full Text] [Related]
27. DAX1, a direct target of EWS/FLI1 oncoprotein, is a principal regulator of cell-cycle progression in Ewing's tumor cells.
García-Aragoncillo E; Carrillo J; Lalli E; Agra N; Gómez-López G; Pestaña A; Alonso J
Oncogene; 2008 Oct; 27(46):6034-43. PubMed ID: 18591936
[TBL] [Abstract][Full Text] [Related]
28. c-Myc-regulated microRNAs modulate E2F1 expression.
O'Donnell KA; Wentzel EA; Zeller KI; Dang CV; Mendell JT
Nature; 2005 Jun; 435(7043):839-43. PubMed ID: 15944709
[TBL] [Abstract][Full Text] [Related]
29. MIF loss impairs Myc-induced lymphomagenesis.
Talos F; Mena P; Fingerle-Rowson G; Moll U; Petrenko O
Cell Death Differ; 2005 Oct; 12(10):1319-28. PubMed ID: 15947793
[TBL] [Abstract][Full Text] [Related]
30. Unbiased analysis of RB-mediated transcriptional repression identifies novel targets and distinctions from E2F action.
Markey MP; Angus SP; Strobeck MW; Williams SL; Gunawardena RW; Aronow BJ; Knudsen ES
Cancer Res; 2002 Nov; 62(22):6587-97. PubMed ID: 12438254
[TBL] [Abstract][Full Text] [Related]
31. The cis-acting elements known to regulate c-myc expression ex vivo are not sufficient for correct transcription in vivo.
Lavenu A; Pournin S; Babinet C; Morello D
Oncogene; 1994 Feb; 9(2):527-36. PubMed ID: 8290263
[TBL] [Abstract][Full Text] [Related]
32. Regulation of human telomerase activity: repression by normal chromosome 3 abolishes nuclear telomerase reverse transcriptase transcripts but does not affect c-Myc activity.
Ducrest AL; Amacker M; Mathieu YD; Cuthbert AP; Trott DA; Newbold RF; Nabholz M; Lingner J
Cancer Res; 2001 Oct; 61(20):7594-602. PubMed ID: 11606399
[TBL] [Abstract][Full Text] [Related]
33. The role of HPV oncoproteins and cellular factors in maintenance of hTERT expression in cervical carcinoma cells.
Jeong Seo E; Jung Kim H; Jae Lee C; Tae Kang H; Seong Hwang E
Gynecol Oncol; 2004 Jul; 94(1):40-7. PubMed ID: 15262117
[TBL] [Abstract][Full Text] [Related]
34. The transcriptional repressor gene Mad3 is a novel target for regulation by E2F1.
Fox EJ; Wright SC
Biochem J; 2003 Feb; 370(Pt 1):307-13. PubMed ID: 12444919
[TBL] [Abstract][Full Text] [Related]
35. Upregulation of c-MYC in WT1-mutant tumors: assessment of WT1 putative transcriptional targets using cDNA microarray expression profiling of genetically defined Wilms' tumors.
Udtha M; Lee SJ; Alam R; Coombes K; Huff V
Oncogene; 2003 Jun; 22(24):3821-6. PubMed ID: 12802290
[TBL] [Abstract][Full Text] [Related]
36. Id2 is dispensable for myc-induced lymphomagenesis.
Nilsson JA; Nilsson LM; Keller U; Yokota Y; Boyd K; Cleveland JL
Cancer Res; 2004 Oct; 64(20):7296-301. PubMed ID: 15492249
[TBL] [Abstract][Full Text] [Related]
37. AP4 encodes a c-MYC-inducible repressor of p21.
Jung P; Menssen A; Mayr D; Hermeking H
Proc Natl Acad Sci U S A; 2008 Sep; 105(39):15046-51. PubMed ID: 18818310
[TBL] [Abstract][Full Text] [Related]
38. Identification of novel E2F1-regulated genes by microarray.
Ma Y; Croxton R; Moorer RL; Cress WD
Arch Biochem Biophys; 2002 Mar; 399(2):212-24. PubMed ID: 11888208
[TBL] [Abstract][Full Text] [Related]
39. Possible involvement of RUNX3 silencing in the peritoneal metastases of gastric cancers.
Sakakura C; Hasegawa K; Miyagawa K; Nakashima S; Yoshikawa T; Kin S; Nakase Y; Yazumi S; Yamagishi H; Okanoue T; Chiba T; Hagiwara A
Clin Cancer Res; 2005 Sep; 11(18):6479-88. PubMed ID: 16166423
[TBL] [Abstract][Full Text] [Related]
40. neu and ras initiate murine mammary tumors that share genetic markers generally absent in c-myc and int-2-initiated tumors.
Morrison BW; Leder P
Oncogene; 1994 Dec; 9(12):3417-26. PubMed ID: 7970700
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
